Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260425 | 0.91 | CYP1A2 (0.46) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL13396251 | 0.86 | CYP1A2 (0.44) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL19012649 | 0.83 | PIK3CD (0.44) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL12139766 | 0.83 | GAA (0.48) | CYP1A2TDP1KDM4EPIK3CDHRH3 | |
| SCHEMBL20329945 | 0.83 | HRH3 (0.40) | CYP1A2TDP1HRH3ALDH1A1 | |
| SCHEMBL15932263 | 0.81 | HRH3 (0.39) | CYP1A2TDP1HRH3ALDH1A1 | |
| SCHEMBL14407779 | 0.81 | CYP1A2 (0.77) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL860793 | 0.81 | CYP1A2 (0.77) | CYP1A2TDP1SMN1; SMN2KDM4EPIK3CD | |
| SCHEMBL37407 | 0.81 | — | — | |
| SCHEMBL22256970 | 0.81 | USP2 (0.49) | CYP1A2TDP1SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20070179140-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070155966-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070004723-A1 | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2007-01-04 | — | — | US | disclosed |
| US-7157473-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | CYP1A2 667/4885TDP1 4269/4885SMN1; SMN2 4210/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | CYP1A2 123/4885TDP1 3191/4885SMN1; SMN2 3545/4885 |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | CYP1A2 3232/4885TDP1 3955/4885SMN1; SMN2 2622/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CYP1A2 4854/4885TDP1 985/4885SMN1; SMN2 1811/4885 |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CYP1A2 3563/4885TDP1 2926/4885SMN1; SMN2 3106/4885 |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | CYP1A2 648/4885TDP1 2246/4885SMN1; SMN2 3440/4885 |
| US-20070179140-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, CCNI | CYP1A2 1388/4885TDP1 2623/4885SMN1; SMN2 2781/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | CYP1A2 1952/4885TDP1 2371/4885SMN1; SMN2 4096/4885 |
| US-20070004723-A1 | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof | HAVCR2, PCNA, HCCS | CYP1A2 367/4885TDP1 4009/4885SMN1; SMN2 3630/4885 |
| US-20070155966-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | HAVCR2, HCCS, NQO1 | CYP1A2 139/4885TDP1 4364/4885SMN1; SMN2 3877/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | CYP1A2 4754/4885TDP1 4237/4885SMN1; SMN2 4232/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | CYP1A2 3276/4885TDP1 274/4885SMN1; SMN2 846/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CYP1A2 3426/4885TDP1 1402/4885SMN1; SMN2 1697/4885 |
| US-20070049586-A1 | 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents | TOP1, TOP2B, DNA2 | CYP1A2 662/4885TDP1 424/4885SMN1; SMN2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.